

DAFTAR PUSTAKA

- Ali, K., Sutaryo, Purwanto, I., Mulatsih, S., Supriyadi, E., Widjajanto, PH., Sumadiono, Nurse, J., 2010. Yogyakarta Pediatric Cancer Registry: An Internasional Collaborative Project of University Gadjah Mada, University of Saskatchewan, and the Saskatchewan Cancer Agency. *Asian Pasific J Cancer Prev*, II, pp.131–6.
- Allen, T. & Cullis, P., 2013. Liposomal drug delivery systems: from concept to clinical applications. *Adv Drug Deliv Rev*, 65(1), pp.36–48.
- American Cancer Society, 2016. *Cancer Facts and Figures 2016*, Available at: <http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf>.
- IDAI, 2013. *Protokol Pengobatan Leukemia Limfoblastik Akut Anak 2013 (Indonesian Childhood ALL - 2013 Protocol)*, IDAI.
- Bharadwaj, S., Ginoya, S., Tandon, P., Gohel, TD., Guirguis, J., Vallabh, H., Jevann, A., Hanouneh, I., 2016. Malnutrition: laboratory markers vs nutritional assessment. *Gastroenterol Rep*, 9(4), p.gow013.
- Bohnert, T. & Gan, L., 2013. Plasma Protein Binding: From Discovery to Development. *J. Pharm. Sci.*, 102(9), pp.2953–2994.
- Bosaeus, I., Daneryd, P., Svanberg, E., Lundholm, K., 2001. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. *Int. J. Cancer*, 93(3), pp.380–383.
- Cooper, S.L. & Brown, P.A., 2015. Treatment of pediatric acute lymphoblastic leukemia. *Pediatr Clin North Am*, 62(1), pp.61–73.

- Creutzig, U., Zimmerman, M., Hanneman, J., Kramer, I., Herold, R., Henze, G., 2003. Quality management within the competence network of paediatric oncology and haematology. *Klin Pad*, 215(6), pp.338–40.
- Curado, M.P., Edwards, B., Shin, H.R., Storm, H., Ferlay, J., Heanue, M., Boyle, P., 2007. *Cancer Incidence in Five Continents Vol. IX*. Lyon: IARC Scientific Publication. Available at: <http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/> [Accessed March 11, 2017].
- Deschler, B. & Lubbert, M., 2008. Acute Myeloid Leukemia : Epidemiology and Etiology. In *Acute Leukemias*. pp. 47–57.
- Dietz, A.C., Sivanandam, S., Konety, S., Kaufman, C.L., Gage, R.M., Kelly, A.S., Neglia, J.P., Mulrooney, D.A., 2014. Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. *J Cancer Surviv*. 8(2), pp.183–9.
- Escherich, G., Zimmerman, M., Janka-Schaub, G., 2013. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. *Pediatr Blood Cancer*, 60(2), pp.254–7.
- European Environment and Health Information System, 2009. Incidence of Childhood Leukaemia. , 2000
- Evans, A.E., Gilbert, E.S. & Zandstra, R., 1970. The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). *Cancer*, 26(2), pp.404–9.
- Ganame, J., Claus, P., Eyskens, B., Uyttebroeck, A., Renard, M., D'hooge, J., et al., 2007. Acute cardiac functional and morphological changes after Anthracycline infusions in children. *Am J Cardiol*, 99(7), pp.974–7.

- Grant, A.D.M., Negishi, K., Negishi, T., Collier, P., Kapadia, S.R., Thomas, J., et al., 2015. Grading diastolic function by echocardiography: hemodynamic validation of existing guidelines. *J Cardiovasc Ultrasound*, 13, p.28.
- Jiji, R.S., Kramer, C.M. & Salerno, M., 2012. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. *J Nucl Cardiol*, 19(2), pp.377–88.
- Klein, K. & Kaspers, G.L., 2013. A Review of Liposomal Daunorubicin in the Treatment of Acute Leukemia. *Oncol Hematol Rev (US)*, 9(2), p.142.
- Kocabaş, A., Kardelen, F., Ertug, H., Aldemir-Kocabas, B., Tosun, O., Yesilipek, A., Hazar, V., Akcurin, G., 2014. Assessment of early-onset chronic progressive anthracycline cardiotoxicity in children: different response patterns of right and left ventricles. *Pediatr Cardiol*, 35(1), pp.82–8.
- Krischer, J.P., Epstein, S., Cuthbertson, D.D., Goorin, A.M., Epstein, M.L., Lipshultz, S.E., 1997. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. *J. Clin. Oncol.*, 15(4), pp.1544–1552.
- Kruger, A. & Wojnowski, L., 2006. Cardiotoxicity of Anthracyclines – an Unsolved Problem. *Dtsch Arztebl*, 103(37), pp.2393–7.
- Lipshultz, S.E., Adams, M.J., Colan, S.D., Constine, L.S., Herman, E.H., Hsu, D.T., et al., 2013. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions: A scientific statement from the American Heart Association. *Circulation*, 128(17), pp.1927–1955.

- Meadows, A.T., Friedman, D.L., Neglia, J.P., Mertens, A.C., Donaldson, S.S., Stoval, S.S., Hammond, S., et al., 2009. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. *J Clin Oncol*, 27(14), pp.2356–62.
- Meluzín, J., Spinarova, L., Bakala, J., Toman, J., Krejci, J., Hude, P., Kara, T., et al., 2001. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. *Eur Heart J*, 22(4), pp.340–8.
- Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., 2004. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. *Pharmacol Rev*, 56(2), pp.185–229.
- Neilan, T.G., Coelho-Filho, O.R., Pena-Herrera, D., Shah, R.V., Jerosch-Herold, M., Francis, S.A., et al., 2012. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. *American Journal Cardiol* 110(11), pp.1679–86.
- Parkin, D., 1998. International incidence of childhood cancer, Vol. II. *IARC Scientific Publication*.
- Rafiyath, S.M., Rasul, M., Lee, B., Wei, G., Lamba, G., Liu, D., 2012. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. *Exp Hematol Oncol*, 1(1), p.10.
- Raj, S., Franco, V.I. & Lipshultz, S.E., 2014. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. *Curr Treat Options Cardiovasc Med*, 16(6), p.315.

- Robert, J., 1993. Epirubicin. Clinical pharmacology and dose-effect relationship. *Drugs*, 45 Suppl 2, pp.20–30.
- Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B.V., Dombernowsky, P., 1998. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. *J Clin Oncol* 16(11), pp.3502–8.
- Sala, A., Pencharz, P. & Barr, R., 2004. Children, cancer, and nutrition--A dynamic triangle in review. *Cancer*, 100(4), pp.677–87.
- Shan, K., Lincoff, A.M. & Young, J.B., 1996. Anthracycline-induced cardiotoxicity. *Ann Intern Med*, 125(1), pp.47–58.
- Simanjorang, C., Kodim, N. & Tehuteru, E., 2013. Perbedaan Kesintasan 5 Tahun Pasien Leukemia Limfoblastik Akut dan Leukemia Mieloblastik Akut pada Anak di Rumah Sakit Kanker “Dharmais”, Jakarta, 1997 - 2008. *Indonesian Journal of Cancer*, 7(1), pp.15–21.
- Simbre II, V.C., Adams, M.J., Deshpande, S.S., Duffy, S.A., Miller, T.L., Lipshultz, S.E., 2001a. Cardiomyopathy Caused by Antineoplastic Therapies. *Curr Treat Options Cardiovasc Med*, 3(6), pp.493–505.
- Swain, S.M., Whaley, F.S. & Ewer, M.S., 2003. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. *Cancer*, 97(11), pp.2869–79.
- Thorn, C.F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., Mcleod, H., Klein, T.E., Altman, R.B., 2011. Doxorubicin pathways: pharmacodynamics and adverse effects. *Pharmacogenet Genomics*, 21(7), pp.440-446.

- Trynda-Lemiesz, L. & Łuczowski, M., 2004. Human serum albumin: spectroscopic studies of the paclitaxel binding and proximity relationships with cisplatin and adriamycin. *J Inorg Biochem*, 98(11), pp.1851–1856.
- Weiss, R.B., 1992. The anthracyclines: will we ever find a better doxorubicin? *Semin Oncology*, 19(6), pp.670–86.
- Wouters, K.A., Kremer, L.C.M., Miller, T.L., Herman, E.H., Lipshultz, S.E., 2005. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. *Br J Haematol*, 131(5), pp.561–78.
- Yeh, E.T.H. & Bickford, C.L., 2009. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. *J Am Coll Cardiol*, 53(24), pp.2231–47.
- Zucchi, R. & Danesi, R., 2003. Cardiac toxicity of antineoplastic anthracyclines. *Curr Med Chem*, 3(2), pp.151–71.